CLAIMS:

1. Use of a compound N-(2-(6-fluoro-lH-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy)benzylamine or a pharmaceutically acceptable salt in the preparation of a medicament for treating Alzheimer's disease by improving or augmenting the effect of ~~an~~ co-administered acetylcholinesterase inhibitor, wherein an effective daily dose of said compound is to be administered to a patient in need of such treatment, and wherein the effective daily dose to be administered to the patient is ~~between about~~ 30 ~~and about~~to 60 mg and the daily dose is administered once daily.

2. Use of a compound N-(2-(6-fluoro-lH-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy)benzylamine or a pharmaceutically acceptable salt co-administered with an acetylcholinesterase inhibitor in the manufacture of a medicament for treating Alzheimer's disease, said medicament being for use as adjunctive therapy to acetylcholinesterase inhibitor treatment ,wherein an effective daily dose of N-(2-(6-fluoro-lH-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy)benzylamine or a pharmaceutically acceptable salt is to be administered to a patient in need of such treatment, and wherein the effective daily dose to be administered to the patient is ~~between about~~ 30 ~~and about~~to 60 mg.

3. The use according to claim 1 or 2, wherein the pharmaceutically acceptable salt is the hydrochloride.

4. The use according to any one of claims 1-3, wherein the dose is administered as an immediate release formulation.

5. The use according to any one of claims 1-4 for treating mild to moderate Alzheimer's disease.

6. The useaccording to any one of claims 1-5, wherein the acetylcholineesterase inhibitor is donepezil.

7. The use according to any one of claims 1-5, wherein the acetylcholineesterase inhibitor is rivastigmine.

8. The use according to anyone of claims 1-5, wherein the acetylcholineesterase inhibitor is galatamine.

9. The use according to any one of claims 1-8, wherein the effective daily dose is 30 mg.

10. The use according to any one of claims 1-8, wherein the effective daily dose is 30 to 40 mg ~~or less~~.

11. The use according to any one of claims 1-8, wherein the effective daily dose is 30 to 50 mg ~~or less~~.

12. The use according to any one of claims 1-8, wherein the effective daily dose is 40 to 60 mg ~~or less~~.

13. The use according to any one of claims 1-8, wherein the effective daily dose is 60 mg.